Vera Therapeutics Inc. (VERA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy
Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but enjoys a commercial head start and broad label.
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression.
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
Vera Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 131 | $4,329.3 | $4,194.62 | -$134.68 | -3.11% |
| BG Bart Gancher Intech Investment Management LLC | 14,829 | $402,439.4 | $487,725.81 | $85,286.41 | 21.19% |
 Anthony Scaramucci SkyBridge Capital II LLC | 300,000 | $11.28M | $9.49M | -$1.79M | -15.89% |
 Point72 Asset Management LP Point72 Asset Management LP | 40,563 | $2.05M | $1.28M | -$771,102.62 | -37.54% |
| NM Nir Messafi Deep Track Capita LLP | 4M | $189.18M | $126.52M | -$62.66M | -33.12% |
Vera Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DR Dina Ramadane B of A Securities | 2,964.81 | $127,368.08 | $98,787.34 | -$28,580.74 | -22.44% |
Vera Therapeutics Inc. (VERA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vera Therapeutics Inc. ever had a stock split?
Vera Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Marshall Fordyce CEO | NASDAQ (NMS) Exchange | 92337R101 CUSIP |
| US Country | 361 Employees | 10 Jan 1996 Last Dividend | - Last Split | 14 May 2021 IPO Date |
Overview
Vera Therapeutics, Inc. is a clinical stage biotechnology firm based in the United States, with a specific focus on addressing serious immunological diseases. Initially founded under the name Trucode Gene Repair, Inc., the company underwent a name change to Vera Therapeutics, Inc. in April 2020. Since its incorporation in 2016, Vera Therapeutics has been headquartered in Brisbane, California, manifesting its commitment to innovation in the biopharmaceutical sector through its active development and commercialization efforts targeting unmet medical needs in immunology.
Products and Services
- Atacicept:
This leading product candidate of Vera Therapeutics is positioned as a groundbreaking fusion protein therapy, administered through subcutaneous injections. Currently, it is undergoing Phase IIb clinical trials, focusing on treating patients with immunoglobulin A nephropathy (IgAN). Atacicept aims to offer a new beacon of hope for patients suffering from this chronic autoimmune disease, potentially altering the course of treatment and improving patient outcomes substantially.
- MAU868:
Another promising candidate from Vera Therapeutics' portfolio is MAU868, a monoclonal antibody that is in Phase 2 clinical trials. This innovative therapy is designed for the treatment of BK viremia infections, a significant complication in transplant recipients that can result in the loss of the transplanted organ. By targeting the BK virus with precision, MAU868 has the potential to significantly reduce the incidence of transplant-related complications, offering a new lifeline to patients undergoing organ transplants.
